Revive is no one trick pony— Massive opportunity in the psilocybin space.
This stock is totally undervalued when you look at the sum of the parts.
Investors should really look under the hood.
Upside apparent.
“Revive has an intellectual property portfolio of psilocybin-based formulations ready to advance to the next stages of clinical development and with our newly-established relationship with Complete Phytochemical Solutions they will bring a wealth of product formulation and testing experience with phytochemicals, including hallucinogenics. Complete Phytochemical Solutions will be instrumental in achieving milestones that will unlock the potential of our psilocybin-based platform,” said Michael Frank, Revive’s Chief Executive Officer.
7 minutes ago · Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin- Based ...